Loading…

GRAIL IncGRALCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Early cancer-detection company developing the Galleri multi-cancer early detection blood test, spun off from Illumina.

Momentum leader 95
Mkt cap
$4.59B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$119M
20-day average traded
P/B
1.86×
price to book
ROE
-17.3%
delivered
Implied ROE
33.5%
what the price asks
Next earnings
99 days
25 Feb 2027
Close · USD$102.10
1D-3.6%
1W-18.7%
1M-18.1%
3M+38.0%
6M+67.4%
YTD+19.3%
1Y+28.2%
ATR %10.7%
Beta2.97
52w lowhigh38.7% off high

What GRAIL does

Early cancer-detection company developing the Galleri multi-cancer early detection blood test, spun off from Illumina.

Sells Galleri as a lab-run blood test ordered by doctors, but most patients pay out of pocket because insurers and Medicare do not generally cover screening yet, so wider coverage depends on trial evidence and regulatory approval. Illumina spun it off in 2024 and no longer controls it.

Products and services

  • Galleri multi-cancer early detection test
  • Diagnostic/confirmatory oncology testing pipeline

Customers

  • Health systems/physicians (screening)
  • Employers/health plans (early-access programs)

Where it sits in the supply chain

  • Healthcare
  • Diagnostics/precision oncology
  • Multi-cancer early detection blood…

What could go right

  • Broader payer reimbursement/coverage for Galleri
  • Screening-guideline adoption

What could go wrong

  • No broad insurance reimbursement yet
  • High cash burn ahead of profitability

Moat: narrow (data, IP / patents, scale). First-mover with a large proprietary genomic dataset in the nascent multi-cancer early-detection category.

Headquarters: Menlo Park, California, USA · Founded: 2016 · Employees: 910

Named competitors

GRAIL at a glance

Size GRAIL (GRAL) is a United States Health Care company (Medical Specialties) with a market value of $4.59B, the 1239th largest of 3,085 United States companies the cockpit tracks. Shares closed at $102.10 on 18 Nov 2026.

Performance Over six months the shares gained 67.4%, against +23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 17.5% over the last twelve months (peer median +7.0%); the operating margin is -332.0% (peer median 13.9%).

Valuation It trades at 1.86× book value against a peer median of 2.71× (6th cheapest of 21).

Price implies The share price implies a return on equity of about 33.5%; GRAIL delivers -17.3%, so the price asks more than the business earns today.

Short interest Short interest is 17.8% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015020025021 May 202621 Aug 202618 Nov 2026GRAL 155Peer median 126
Six months, rebased to 100: GRAIL against the median of its 20 peers (local-currency closes).

GRAIL financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$167M$147M$126M$93.1M$55.5M
Revenue growth—+17%+35%+68%—
Gross profit-$63.0M-$77.4M-$78.0M-$95.6M-$116M
EBITDA-$398M-$378M-$570M-$638M-$588M
Net income-$406M-$408M-$2.03B-$1.47B-$5.40B
Free cash flow-$312M-$300M-$582M-$609M-$584M
Capital expenditure$5.76M$909,000$5.21M$12.9M$22.9M
Total debt$85.8M$54.9M$68.1M$84.4M$96.0M

Quarterly statements and history in the cockpit →

GRAIL competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%0%+20%SHCICUIMMEDDIA300677STVN002223MMSILIVNFIECDNA002432NVSTHAE1SXP603014TECN4203688617AMBU-BGRAL6-month return →1-month return →
Up and to the right = strong over both horizons. GRAIL is the large dot.

Fundamentals: return on equity against price-to-book

0%20%2.50×50×7.50×SHCICUIMMEDDIA300677STVN002223LIVNFIECDNA002432NVSTHAE1SXPTECN4203688617AMBU-BGRALReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. GRAIL is the large dot.

Capital: ROE delivered against the ROE the price implies

0%50%100%0%50%100%SHCICUIDIA300677LIVNFIECDNA002432HAE603014TECN688617GRALROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. GRAIL is the large dot.

GRAIL competitors and peer comparison

Head to head with its named competitors (GRAL vs GH)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
GRAIL GRAL$4.59B+67%+17%-17%1.86×33.5%
Guardant Health GH$19.6B+26%+42%n/an/an/a

How GRAIL compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GRAIL against its 20 peers (data as of 18 Nov 2026)
MeasureGRALPeer medianRank in peer set
1-month return-18.1%+5.5%3rd lowest of 21
6-month return+67.4%+23.4%3rd highest of 21
Return on equity-17.3%10.3%lowest of 21
Price / book1.86×2.71×6th cheapest of 21
ROE the price implies33.5%16.4%4th most demanding of 21
ROE delivered-17.3%10.5%lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
GRAIL GRALUnited States$4.59B+67%+17%-17%1.86×33.5%-17.3%
Sotera Health SHCUnited States$4.65B+5%+7%27%6.34×77.7%27.0%
ICU Medical ICUIUnited States$4.46B+38%-6%3%2.04×16.2%2.8%
MiniMed MMEDUnited States$4.78B+46%+14%-10%1.32×7.7%n/a
DiaSorin DIA.MIItaly$4.81B+24%-3%10%2.82×13.2%9.5%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%2%1.78×9.7%1.6%
Stevanato STVNUnited States$4.19B-13%+12%9%2.32×17.1%9.3%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%9%2.15×10.2%8.7%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%10%2.95×17.3%9.8%
LivaNova LIVNUnited States$5.21B+28%+12%16%3.80×28.1%15.5%
Fielmann FIE.DEGermany$3.92B-3%+3%21%3.25×13.1%20.6%
CareDx CDNAUnited States$3.91B+252%+39%33%8.35×125.1%33.0%
Andon Health 002432.SZChina$3.86B-24%-30%25%0.94×3.5%24.7%
Envista NVSTUnited States$3.81B0%+10%21%1.23×11.3%20.5%
Haemonetics HAEUnited States$5.59B+106%+4%12%6.22×35.4%11.9%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%3.42×18.6%14.7%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%7%2.23×7.0%7.5%
Tecan TECN.SWSwitzerland$3.60B+59%-4%-10%2.61×14.0%-9.7%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%10%1.64×18.9%10.2%
APT Medical 688617.SSChina$6.06B+23%+28%32%11.73×28.5%31.9%
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%10%3.72×16.5%10.5%

Questions

Who are GRAIL's main competitors?
Named competitors: Exact Sciences (private or unlisted), Guardant Health (GH). The cockpit's measured peer set (industry) also includes Sotera Health (SHC), ICU Medical (ICUI), MiniMed (MMED), DiaSorin (DIA.MI), Intco Medical Technology (300677.SZ), Stevanato (STVN).
Is GRAIL expensive compared with its peers?
On price / book it trades at 1.86× against a peer median of 2.71×, 6th cheapest of 21 in its peer set. The share price implies a return on equity of about 33.5%; GRAIL delivers -17.3%, so the price asks more than the business earns today.
How has GRAIL stock performed?
Over six months to 18 Nov 2026 the shares returned +67.4% against +23.4% for the median peer; over one year +28.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.